Latest news
Early Lung Cancer Just Became a Biomarker Test of the System
New Phase III ELEVATE data published in NEJM show adjuvant ensartinib sharply reduced recurrence risk after resection in ALK-positive NSCLC. The science is clear. The access question is whether early-stage lung cancer pathways can test fast enough to use it.
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
The AMR Pipeline Is Too Thin for the Threat Ahead
TB Diagnosis Moves Closer to the Patient
Hepatitis Elimination Is Still Losing Patients Before Diagnosis
Lenacapavir Turns HIV Prevention Into an Access Stress Test
WHO’s AMR Plan Turns Access Into Preparedness
Diabetic Eye Screening Is Becoming Risk-Based
Abu Dhabi Puts Rare Eye Gene Therapy on the Regional Map
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.